(S)-JNJ-1013
(S)-JNJ-1013 is an isomer of IRAK1 PROTAC degrader JNJ-1013 (HY-153188). (S)-JNJ-1013 loses VHL binding affinity (IC50 >10 μM) and shows no significant IRAK1 degradation activity (DC50 > 10 μM). (S)-JNJ-1013 selectively inhibits IRAK1 with an IC50 of 79 nM. (S)-JNJ-1013 can be used to study cancers dependent on the scaffolding function of IRAK1.
(Pink: IRAK1 ligand (HY-138834); Blue: VHL ligand (HY-184855); Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 2755075-91-1
- Formula: C46H55N9O7S
- Molecular Weight:878.05
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
IRAK1 79 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK-293T | DC50 |
3.3 nM
|
IRAK1 protein degradation potency in HEK293T cells measured by immunoblotting after 24 h of treatment.
IRAK1 protein degradation potency in HEK293T cells measured by immunoblotting after 24 h of treatment.
|
34279092 |
| HBL1 | DC50 |
3.0 nM
|
IRAK1 protein degradation potency in HBL-1 ABC DLBCL cells measured by immunoblotting after 24 h of treatment.
IRAK1 protein degradation potency in HBL-1 ABC DLBCL cells measured by immunoblotting after 24 h of treatment.
|
34279092 |
| OCI-Ly10 | DC50 |
20 nM
|
IRAK1 protein degradation potency in OCI-LY10 ABC DLBCL cells measured by immunoblotting after 24 h of treatment.
IRAK1 protein degradation potency in OCI-LY10 ABC DLBCL cells measured by immunoblotting after 24 h of treatment.
|
34279092 |
| HBL1 | IC50 |
60 nM
|
Antiproliferative activity against HBL-1 ABC DLBCL cells assessed as reduction in cell viability incubated for 12 days by CTG assay.
Antiproliferative activity against HBL-1 ABC DLBCL cells assessed as reduction in cell viability incubated for 12 days by CTG assay.
|
34279092 |
| OCI-Ly10 | IC50 |
170 nM
|
Antiproliferative activity against OCI-LY10 ABC DLBCL cells assessed as reduction in cell viability incubated for 12 days by CTG assay.
Antiproliferative activity against OCI-LY10 ABC DLBCL cells assessed as reduction in cell viability incubated for 12 days by CTG assay.
|
34279092 |
In Vitro
(S)-JNJ-1013 (Compound degrader-4) (1 μM) exhibits high kinome selectivity for IRAK1 in a cell-free KinomeScan competitive binding assay[1].
(S)-JNJ-1013 potently inhibits IRAK1 kinase activity in cell-free biochemical assays, with an IC50 of 79 nM[1].
(S)-JNJ-1013 (for 12 days) inhibits the proliferation of HBL-1 ABC DLBCL cells with an IC50 of >1.5 μM; it also inhibits the proliferation of OCI-LY10 ABC DLBCL cells, with an IC50 of >3 μM after 12 days of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 2755075-91-1
-
Molecular Weight 878.05
-
Formula C46H55N9O7S
-
SMILES
COC(C=C1N(CC2)CCC2OCC(N[C@@H](C(C)(C)C)C(N3[C@@H](C[C@@H](C3)O)C(N[C@H](C4=CC=C(C5=C(C)N=CS5)C=C4)C)=O)=O)=O)=C(C=C1)NC(C6=CC=CC(C7=NNC=C7)=N6)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)